Researchers at the University of Utah are investigating photobiomodulation therapy (itPBM)—a medical-grade red-light approach delivered through intranasal transcranial treatment—to see whether it can help people with traumatic brain injuries and concussion-related effects. Reporting highlights claims from adjunct professor Larry Carr and colleagues that the therapy may reduce brain inflammation and support cognitive and mental health measures, including cognition, mood, anxiety, and aspects of motor performance.
A key focus is research discussed by multiple outlets that includes a season-long study of 26 BYU football players. The reporting says players who did not receive treatment showed significant, widespread brain inflammation, while the treated group did not show comparable increases and sometimes showed reduced inflammation in some brain regions. Researchers involved in the work describe the findings as “striking,” and they cite additional peer-reviewed studies and imaging results suggesting links to improvements in cognitive, emotional, attention, and motor-related outcomes.
At the same time, both sources stress that definitive clinical trials are not yet completed and that broader validation is required. Outside experts cited in the coverage note that the findings are promising but not conclusive, and they caution that itPBM is not presented as a cure-all. Skepticism also appears in the reporting, even as researchers argue the results justify further study.